South & Central America Generic Drugs Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The South & Central America generic drugs market size is expected to reach US$ 26,947.56 million by 2031 from US$ 23,676.82 million in 2024. The market is estimated to record a CAGR of 1.9% from 2025 to 2031.

Executive Summary and South & Central America Generic Drugs Market Analysis:

The generic drugs market in South and Central America is segmented into Brazil, Argentina, and the rest of South and Central America. According to the Inter-American Development Bank (IDB), non-communicable diseases (NCDs) account for approximately 77% of all deaths and 70% of the total disease burden in Latin America and the Caribbean. The increasing burden of NCDs underscores the need for affordable, long-term treatment options, with generic medications playing a pivotal role. Governments in the region have implemented public health initiatives to improve access to essential medicines. In Brazil, the Farmácia Popular program-backed by the Ministry of Health-provides subsidized or free medications for chronic diseases such as hypertension and diabetes to millions of citizens. According to the Pan American Journal of Public Health, the Programa Remediar distributes free essential generic drugs through public primary healthcare centers, improving access among underserved populations in Argentina. Despite regulatory and supply chain challenges, the demand for generic drugs is rising, bolstered by local and international efforts to expand access and manufacturing capabilities. Eurofarma, one of Brazil's leading pharmaceutical companies, has entered into multiple licensing and manufacturing agreements with multinational firms to enhance local production and broaden its portfolio of generic drugs.

South & Central America Generic Drugs Market: Strategic Insights

South & Central America Generic Drugs Market Segmentation Analysis:

Key segments that contributed to the derivation of the South & Central America generic drugs market analysis are molecule type, indication, type, and distribution channel.

• Based on molecule type, the South & Central America generic drugs market is segmented into antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. The antibiotics segment held the largest share of the market in 2024.

• By indication, the South & Central America generic drugs market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare diseases, and others. The cancer segment held the largest share of the market in 2024.

• Based on type, the South & Central America generic drugs market is bifurcated into prescription and OTC drugs. The prescription segment held a larger share of the market in 2024.

• By indication, the South & Central America generic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2024.

South & Central America Generic Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The South & Central America Generic Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

South & Central America Generic Drugs Market Outlook

Biosimilars are gaining prominence in the global generic drugs market, influenced by several key trends. The expiration of patents for major biologic drugs has paved the way for biosimilars, offering more affordable alternatives and contributing to reduced healthcare costs. Regulatory agencies such as the FDA and EMA have established streamlined approval processes for biosimilars, facilitating their timely market entry. This has led to increased acceptance among healthcare providers, supported by real-world evidence and successful clinical trials demonstrating their safety and efficacy. As more biologic patents expire, the market has become more competitive, prompting pharmaceutical companies to invest in biosimilar development. Additionally, biosimilars are gaining traction in emerging markets, enhancing access to essential biologic treatments at reduced costs. As per the WHO, noncommunicable diseases (NCDs), including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes, are the leading causes of death and disability worldwide. In 2019, NCDs accounted for 41 million of the 55 million global deaths, representing 75% of all deaths that year. Furthermore, ~18 million NCD-related deaths occurred before the age of 70, with 82% of these premature deaths in low- and middle-income countries. As per the UN, the global burden of NCDs is projected to increase, with estimates suggesting that by 2050, chronic diseases will account for 86% of the 90 million deaths annually, a 90% increase in absolute numbers since 2019.

The escalating prevalence of chronic diseases underscores the critical need for effective prevention and management strategies. Biosimilars play a vital role in this context by providing cost-effective treatment options, thereby improving access to necessary therapies and alleviating the financial burden on healthcare systems and patients.

South & Central America Generic Drugs Market Country Insights

Based on country, the South & Central America generic drugs market comprises Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest share in 2024.

According to the Brazilian Health Regulatory Agency (ANVISA), in 2023, generics account for over 40% of total pharmaceutical sales in Brazil. The country's Popular Pharmacy Program (Farmácia Popular), which provides essential medications at reduced costs through a public-private partnership, has made generic medicines available to lower-income populations. The government's policies promoting the production of generics and biosimilars have driven down prices, ensuring that more patients have access to life-saving drugs. Companies such as EMS and Libbs are among the leading generic drug manufacturers, helping Brazil become one of the world's largest producers of generic medications. Brazil's local manufacturing capabilities allow it to meet domestic demand for generics and export them to other countries. However, one of the primary obstacles is the complex regulatory environment. ANVISA, Brazil's health regulatory agency, ensures that generics meet the same standards as their branded counterparts, but the approval process can be slow and cumbersome. This process can delay the entry of new generics to the market and prevent patients from benefiting from affordable options. Another challenge is the price sensitivity of consumers, particularly in the public healthcare system. While generics are generally more affordable than branded drugs, they remain out of reach for lower-income groups, especially when access to generic drugs is inconsistent in remote or underserved areas. The patent disputes between generic manufacturers and brand-name companies can delay the introduction of generics to the market, limiting competition and keeping prices high. As the population ages and the prevalence of chronic diseases increases, the demand for affordable medications rises. With several biologic patents expiring in the coming years, Brazil is well-positioned to expand its biosimilar market, which will offer cost-effective alternatives to expensive biologic treatments for cancer and autoimmune diseases.

South & Central America Generic Drugs Market Company Profiles

Some of the key players operating in the market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

South & Central America Generic Drugs Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.

• Industry trade journals and other relevant publications.

• Government documents, statistical databases, and market reports.

• News articles, press releases, and webcasts specific to companies operating in the market.

Note:

All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.

• Enhance the expertise and market understanding of the analysis team.

• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers

• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise